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phe investigators of the recently published ASTRAL
Angioplasty and Stenting for Renal Artery Le-
ions) trial concluded that there was “substantial risk
ithout worthwhile clinical benefit from revascular-
zation in patients with atherosclerotic renovascular
isease” (1). We believe that the unconventional
tudy design and significant methodologic flaws of
his trial led to inaccurate, somewhat hysterical, con-
lusions (1,2).
ASTRAL was a multicenter, randomized, un-
linded clinical trial conducted in Europe and
ustralia. Patients were eligible for inclusion if
linical findings (hypertension or unexplained renal
ysfunction) suggested a diagnosis of renal artery
tenosis (RAS), imaging studies confirmed stenosis
n at least 1 renal artery, and if the physician was
ncertain that the patient would benefit from
evascularization. Patients were excluded if they
equired surgical revascularization or were consid-
red to have a high likelihood of requiring revas-
ularization within 6 months. This is a flawed
nrollment strategy, excluding the very patients
ho should have been randomized in a clinical
rial.
Very unconventional for a trial of this size was
he lack of an objective “core” laboratory to adju-
icate or validate the on-site visual estimates of
AS. The absence of objective oversight and
eliance on visual estimation make it very likely
hat the degree of renal artery narrowing was
verestimated (3). Overestimation of RAS creates
significant bias against revascularization because
hese mild lesions are not likely to be causing renal
ypoperfusion that would benefit from percutane-
us renal intervention (PRI). Overestimation of
AS stenosis also creates a bias in favor of the
edical therapy (MT) group because the milder
rom the *Division of Cardiovascular Medicine, Deborah Heart and
ung Center, Browns Mills, New Jersey; and the †Department ofs
ardiovascular Diseases, The John Ochsner Cardiovascular Institute,
chsner Clinic Foundation, New Orleans, Louisiana.esion would be less likely to cause significant
schemia, progress in severity, or any harm to the
atient.
The trial enrolled 806 patients (403 patients in
he PRI group and 403 patients in the MT group)
rom 2000 to 2007 to be followed over a 5-year
eriod. Patients were randomly assigned to un-
ergo PRI with MT or to receive MT alone.
lthough the baseline characteristics appeared
imilar, 40% (nearly one-half) of the patients in
oth groups had RAS 70%, which is another
ource of significant bias against PRI. Not only
ere 40% of study patients not likely to benefit
rom revascularization of a mild stenosis, the risk of
urther loss of renal function with medical therapy
s also unlikely. The ASTRAL investigators failed
o recognize or acknowledge that there is no
linical equipoise in randomizing mild RAS lesions
o revascularization.
Only 83% of patients randomized to revascular-
zation actually underwent PRI. Of those random-
zed to revascularization, only 78.6% had a success-
ul procedure. This success rate is far below the
6% to 98% success rate expected in clinical prac-
ice and another major source of bias against
ntervention programmed into this poorly con-
tructed trial (4). Moreover, there was a serious
omplication rate of 9% in the PRI group, which is
ar higher than that reported in current clinical
rials (4–8). Questionable operator renal interven-
ion skills further weaken the conclusions reached
n ASTRAL. During the 7 years of recruitment, 24
enters randomized between 1 and 5 patients (42%
f all randomized patients) and 35 centers random-
zed 10 patients (65% of all randomized pa-
ients). This implies that 65% of all participating
enters randomized 1 patient per year! The
STRAL investigators would not qualify as high-
olume interventionalists.
The end points are compromised by the trial’s
oor study design. Change in renal function cannot
erve as a legitimate outcome measure when 25%
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787f the patients in each group had normal baseline renal
unction and an additional 15% had near-normal renal
unction. The secondary end point of blood pressure im-
rovement is also questionable when the mean number of
ntihypertensive drugs per patient in each treatment group
as only 2.8, which is less than the requirement of 3
ntihypertensive medications recommended by the Ameri-
an College of Cardiology/American Heart Association
ractice guidelines before revascularization (9).
As stated earlier, the primary and secondary end points
re poor outcome measures based on this study design
andomizing patients with uncertain indications for revas-
ularization. Despite multiple biases against intervention
uilt into this trial, there was a significant decrease in mean
ystolic blood pressure at 3 months after revascularization
p  0.05) and a lower average number of antihypertensive
gents at 1 year (p  0.03) in the PRI group.
ummary
he ASTRAL trial was a severely flawed study that inap-
ropriately concluded that the risks of renal stenting were
ot justified by the benefits. The conclusion should have
een that patients with mild RAS have little to benefit from
enal stent placement. Perhaps future trials—such as
ORAL (Cardiovascular Outcomes in Renal Atheroscle-
otic Lesions), RADAR (Randomised multi-centre pro-
pective study comparing best medical treatment versus best
edical treatment plus renal artery stenting in patients with
emodynamically relevant atherosclerotic renal artery steno-
is), and NITER (Nephropathy Ischemic Therapy)—esigned to evaluate treatment strategies in hemodynami-
ally significant RAS will shed light on the true outcomes of
enal artery revascularization.
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enter, 200 Trenton Road, Browns Mills, New Jersey 08015.
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